GotoPER - Physicians' Education Resource
Back to Home
Free CE/CMEVideo

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Create AccountAlready Registered? Login Here

Release Date

June 5, 2026

Expiration Date

July 1, 2026

Credits

2.0 CME, NCPD

Specialties

Lung Cancer, New Drugs+1 more

Activity Overview

This educational activity is an archive of the live presentation held on May 31, 2026.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care providers who manage patients with early-stage non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the role of key actionable biomarkers and current molecular testing strategies in advanced NSCLC
  • Evaluate recent clinical trial data on approved and emerging targeted therapies and immunotherapies for advanced NSCLC
  • Apply molecular profiling results and clinical characteristics to develop individualized treatment plans for patients with advanced NSCLC
    Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

    GET STARTED WITH THIS PROGRAM:

    Register now to gain access to this program.

    Create AccountAlready Registered? Login Here

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

    Acknowledgment of Commercial Support

    This activity is supported by educational grants from BioNTech; Iovance Biotherapeutics, Inc; Lilly; Nuvation Bio; Revolution Medicines, Inc; and Rigel Pharmaceuticals.

    Follow Us on Social Media!

    Related Content

    PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the EvidenceFree CE/CME

    PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

    PER Global Perspectives: Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity DifferentiationVirtual Event

    PER Global Perspectives: Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

    Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment ModalitiesFree CE/CME

    Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

    Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung CancerFree CE/CME

    Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

    Course

    Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

    Create Account